Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.
You may also be interested in...
GlaxoSmithKline
NicoDerm CQ transdermal patch marketer signs development/commercialization deal with Taisho Pharmaceutical for OTC smoking cessation products in Japan. GSK will supply products, while Taisho will handle sales, distribution. Agreement comes on heels of Japan Ministry of Health's June 20 approval of Pharmacia's Nicorette gum as first OTC smoking cessation aid (1"The Tan Sheet" July 2, In Brief)
GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes
GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.
Generic Nicotine Replacement Products Start To Smoke In 2000
Private label OTC smoking cessation products thrived in 2000, their first full year on the food, drug and mass market, recording sales well over $100 mil. and capturing nearly a 20% dollar share, according to data from Information Resources, Inc. (Chicago).